

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09/785,895</u>	Prepared by <u>DLP</u>	Tracking Number <u>05995796</u>	
Examiner-GAU <u>Lacarciera-1635</u>	Date <u>9/13/04</u>	Week Date <u>8/16/04</u>	
	No. of queries <u>2</u>	<u>1FW(E)</u>	

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	<u>(p.) PTO-1449</u>
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

- a. Page Missing
- b. Text Continuity
- c. Holes through Data
- d. Other Missing Text
- e. Illegible Text
- f. Duplicate Text
- g. Brief Description
- h. Sequence Listing
- i. Appendix
- j. Amendments
- k. Other

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text
- k. Other

MESSAGE

^① PTO-1449: Please initial or line through citations on form dated 2/12/04. (copy provided for reference).

^② references on Two(2) pro-892 forms are illegible. (see attached). please provide legible/clearer copies.

Thank You
initials DLP

RESPONSE

initials

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-081-A

Serial No.

09/785,895

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Applicant:

Belardinelli et al.

Filing Date:

February 16, 2001

Group:

1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	5.	5,530,101	June 25, 1996	Queen et al.			
	6.	5,585,089	Dec 17, 1996	Queen et al.			
	7.	6,060,481	May 9, 2000	LaNoue et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	11.	WO 00/73307	Dec 7, 2000					
	12.	WO 00/51621	Sept 8, 2000					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	20.	Morrison, (1992) <i>Ann. Rev. Immunol.</i> 10:239-65.
	21.	Presta, (1992) <i>Curr. Op. Struct. Biol.</i> 2:593.
	22.	Reichmann et al., (1988) <i>Nature</i> 332:323.
	23.	Reisener et al., (1998) <i>Trends in Biotechnol.</i> 16:242-246.
	24.	Spria et al., (1984) <i>J. Immunolog. Meth.</i> 74:307.
	25.	Stepiweski et al., (1985) <i>P.N.A.S. U.S.A.</i> 82:8653.
	26.	Wright et al., (1992) <i>Crit. Rev. Immunol.</i> 12:125-68.
	27.	International Search Report for International Application PCT/US02/25713.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

Notice of References Cited

Application/Control No

09/785.895

Applicant's Patent Office
Reexamination

BELARONNE

Examiner

Mary Schmidt

1998

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author Title Date Publisher Edition or Volume Part of a Series				
	U	B.K. Kemp et al., Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. JOURNAL OF PHARMACOLOGY (1999) 126, pp. 1796-1800 ✓				
	V	W. Michael Flanagan et al., Cellular penetration and antisense activity by a phenoxazine - substituted heparan derivative. RESEARCH, pp. 1-5 ✓ D				
	W	Andrea D. Branch, A good antisense molecule is hard to find. TIBS 23 - February 1998, pp. 41-42. ✓ D				
	X	K. N. Klotz et al., Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected CHO cells. NAUNYN - SCHMIEDEBERG'S ARCH PHARMACOL (1998) 357 pp. 1-9 ✓				

*A copy of this reference is not being furnished with this Office action. (See MPEP § 201.18(a))

Dates in MM-YYYY format are publication dates. Classifications may be different from those shown.

Notice of References Cited

Application/Control No.

09/785 895

Examiner

Mary Schmidt

Applicant's Patent Agent

Reexamination

by: 09/04/2000

Date

Page

10/1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name
	A	US-		
	B	US-		
	C	US-		
	D	US-		
	E	US-		
	F	US-		
	G	US-		
	H	US-		
	I	US-		
	J	US-		
	K	US-		
	L	US-		
	M	US-		

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name
	N				
	O				
	P				
	Q				
	R				
	S				
	T				

NON-PATENT DOCUMENTS

*		Include as applicable	Author	Title	Date	Publisher	Edition or Volume	Page(s)
	U		Yong-Chul Kim et al.,	Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS 15943) Inhibit Human A2B and A3 Receptor Subtypes.	J. MED. CHEM. 1998, 41	pp 2835-2845		✓
	V		Maria B. Grant et al.,	Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Endothelial Cells.	CIRCULATION RESEARCH	pp. 699-706	October 15, 1999	✓
	W		Anders Kvanta et al.,	Localization of Adenosine Receptor Messenger RNAs in the Rat Eye.	EXP. EYE RES.	1997, 65	595-602	✓
	X							

*A copy of this reference is not being furnished with this Office action. (See MPEP § 1308.01(a))
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.